Impax, Schering Patent Litigation Continues Despite Claritin-D Agreement

Impax Labs' agreement to supply Schering-Plough with Claritin-D 12-Hour for OTC sale is not expected to attract Federal Trade Commission scrutiny due to its nonexclusivity provisions and lack of impact on pending patent litigation, the generics firm said